Search company, investor...

Chameleon BioSurfaces

Founded Year



Acquired | Acquired

About Chameleon BioSurfaces

Chameleon BioSurfaces is developing polymer coatings for implantable medical devices, such as drug eluting stents. Unlike current generation polymers, which are spray- or dip-coated on to devices, the company's coatings are polymerised directly from the metal surface using a patented electrodeposition process, and can be derivatised according to clinical requirements.

Headquarters Location

10 Wellington Street

CB1 1HW,

United Kingdom

Missing: Chameleon BioSurfaces's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Chameleon BioSurfaces's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Chameleon BioSurfaces News

Device Coating Startup Biotectix Buys IP From Chameleon BioSurfaces

Mar 28, 2011

XconomyDetroit/Ann Arbor —  Biotectix is putting some of its new financial firepower to work. The Ann Arbor, MI-based startup, a spinoff from the University of Michigan, said Monday that it acquired the intellectual property portfolio of Chameleon BioSurfaces in Cambridge, England. Terms of the deal were not disclosed. Biotectix is developing polymer materials designed to improve how implantable medical devices interact with the body and tissues, over time, such as by enhancing stability and preventing foreign body reactions to the devices. Last fall, the company received a $3 million investment from Allied Minds , which makes seed investments in technology developed at universities and national labs. It first backed Biotectix in February 2009, alongside Ann Arbor Spark, which invested through its Michigan Pre-Seed Capital Fund. Chameleon’s advanced polymer coating technology features electroconductive properties that can better control the release of drugs from implantable medical devices. For example, drug eluting stents (tiny devices that prop open clogged arterties) can release drugs over time that prevents the blood vessels from reclosing. “The Chameleon technology is highly complementary to the…polymer materials we are actively commercializing,” Biotectix general manager Dr. James Arps said in a statement. “Importantly, it further solidifies our leading IP position in this field while giving us additional materials options with our co-development partners in the medical device field.”

Chameleon BioSurfaces Frequently Asked Questions (FAQ)

  • When was Chameleon BioSurfaces founded?

    Chameleon BioSurfaces was founded in 2004.

  • What is Chameleon BioSurfaces's latest funding round?

    Chameleon BioSurfaces's latest funding round is Acquired.

  • Who are the investors of Chameleon BioSurfaces?

    Investors of Chameleon BioSurfaces include Biotectix, London Seed Capital, NW Brown, Create Partners, UK Innovation & Science Seed Fund and 8 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.